Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Docetaxel as ≥2nd-line Therapy for Advanced Non-squamous NSCLC
ChiCTR1900023186Phase 4Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- May 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib and docetaxel in Non-small cell lung cancer (NS-NSCLC), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Objective response rate (ORR) within 3 months. Started May 2019; status: recruiting.
02
Drugs
anlotinibdocetaxel
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR1900023186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023186.